Karen Knudsen: MCEDAct creates a pathway to ensure timely Medicare coverage
Karen Knudsen shared a post by American Cancer Society Cancer Action Network, on X:
“In 2024, over 1 million Americans over the age of 65 are expected to be diagnosed with cancer. This Act creates a pathway to ensure timely Medicare coverage of new, innovative multi-cancer screening tests and expand access to early detection once clinical benefit is shown.”
Quoting American Cancer Society Cancer Action Network’s post:
“Tomorrow, Ways and Means Committee + Ways and Means Democrats will mark-up the bipartisan MCEDAct—important legislation with the potential to make a meaningful difference in the lives of Medicare enrollees and their families by ensuring access to early cancer detection.“.
Read further.
Source: Karen Knudsen/X and American Cancer Society Cancer Action Network/X
Karen E. Knudsen, MBA PhD, is the CEO of both the American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN).
Dr. Knudsen is known for her practice-changing research in prostate cancer, which has contributed to new, effective cancer treatments.
She also holds several thought leadership roles, including advisory positions with the National Cancer Institute and the American Society for Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023